According to Alnylam Pharmaceuticals latest financial reports the cash on hand of ALNY is $2.44B, an increase of 11.27% to 2022. At the end of 2022 company had $2.19B cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $2.44B | 11.27% |
2022 | $2.19B | -9.98% |
2021 | $2.44B | 29.94% |
2020 | $1.87B | 22.02% |
2019 | $1.54B | 41.69% |
2018 | $1.08B | - |